Spruce Biosciences (SPRB) Depreciation & Amortization (CF) (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Depreciation & Amortization (CF) of $252000.0 for Q1 2026, up 4100.0% year-over-year from $6000.0 in Q1 2025, and up 4940.0% quarter-over-quarter from $5000.0 in Q4 2025.
Spruce Biosciences (SPRB) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $252000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4100.0% year-over-year to $252000.0; the TTM figure through Mar 2026 stood at $267000.0 (up 621.62% YoY), while the FY2025 annual figure was $21000.0, down 54.35% from the prior year.
- Depreciation & Amortization (CF) improved to $252000.0 in Q1 2026 per SPRB's latest filing, from $5000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $252000.0 in Q1 2026 and bottomed at $3000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $27235.3 across 5 years, with a median of $15000.0 in 2024.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) plunged 70.0% — and 2026, when it surged 4100.0%.
- Spruce Biosciences' Depreciation & Amortization (CF) stood at $24000.0 in 2022, then plunged by 33.33% to $16000.0 in 2023, then sank by 43.75% to $9000.0 in 2024, then sank by 44.44% to $5000.0 in 2025, then surged by 4940.0% to $252000.0 in 2026.
- Business Quant data shows SPRB's Depreciation & Amortization (CF) at $252000.0 in Q1 2026, $5000.0 in Q4 2025, and $3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 631,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 631,000.00 |
| Jun 30, 2026 | 631,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |